p style=”text-align:center;font-size:12px;line-height:1.35;margin:0 0 12px;”>FILE: NHS signage at Queen Elizabeth Hospital in Woolwich, April 17, 2018. Photo: Paul W, CC BY-SA 4.0, via Wikimedia Commons; cropped and resized. Not a photograph of the retifanlimab rollout. The cropped photograph is licensed under CC BY-SA 4.0; the article text is not covered by that license.
NHS England is making the immunotherapy retifanlimab available to eligible adults with advanced anal cancer from November 12, following a new NICE recommendation and an earlier regulatory approval.About 250 people a year in England could benefit, according to NHS England and NICE. The treatment, sold by Incyte Biosciences as Zynyz, is used with chemotherapy for squamous cell carcinoma of the anal canal that has spread or returned locally and cannot be removed by surgery.
The announcement concerns access through England’s health system. It is not a new U.S. drug approval or a cure for anal cancer.
Recommendation and Approval Are Separate
NICE published final draft guidance recommending retifanlimab alongside platinum-based chemotherapy on November 12. NHS England said rollout can begin immediately through the Cancer Drugs Fund.
The Medicines and Healthcare products Regulatory Agency announced the drug’s approval for this indication on November 11, but its notice says the approval itself was granted November 5. Those dates distinguish regulatory permission from the new NHS access announcement.
Retifanlimab targets PD-1, a receptor involved in regulating the immune response, to help immune cells recognise and attack cancer cells. It is given by intravenous infusion once every four weeks, initially with carboplatin and paclitaxel. MHRA says chemotherapy accompanies the first six treatment cycles.
What the Trial Found
The randomized POD1UM-303/InterAACT-2 trial enrolled 308 patients and compared retifanlimab plus carboplatin and paclitaxel with placebo plus the same chemotherapy.
A published analysis reported median overall survival of 32.8 months with retifanlimab and chemotherapy, compared with 22.2 months in the comparison group. Median time before disease progression or death was 9.3 months versus 7.4 months in the primary analysis.
These are study-group medians, not a promise of a particular survival time for an individual patient. The research was published before the NHS rollout; November 12 is the access announcement, not the release of new trial results.
Treatment also carries risks. The published analysis reported adverse events leading to treatment discontinuation in 11.7% of patients receiving retifanlimab and chemotherapy, compared with 2.6% in the placebo-and-chemotherapy group. MHRA directs patients and clinicians to the medicine’s official information for the full side-effect list.
NICE said Incyte has a commercial arrangement that supplies the drug to the NHS at a confidential discount. The announcement did not disclose the discounted price.
Sources: NHS England rollout, NICE recommendation, MHRA approval notice, and published trial analysis.
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
